Clinical Research Directory
Browse clinical research sites, groups, and studies.
Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer
Sponsor: Oliver Jonas
Summary
This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 20 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against lung cancer or mesothelioma. The name of the intervention(s) involved in this study are: Implantable Microdevice (IMD) Surgery (excision of tumor) Drugs used in this study will include drugs already used as standard of care for the treatment of lung cancer and mesothelioma, or other drugs that are approved or being investigated for these indications.
Official title: Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Responses in Lung Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-10-30
Completion Date
2031-10-30
Last Updated
2026-10-23
Healthy Volunteers
No
Interventions
Implantable Micro- drug delivery Microdevice (IMD)
Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques. Drugs will include selected anticancer agents, such as methotrexate, gemcitabine, pemetrexed, paclitaxel, ipilimumab, nivolumab, pembrolizumab, carboplatin, abemaciclib, vinorelbine, etoposide, and osimertinib.